The dose-response relationship of remimazolam in the induction of anesthesia in children

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061886

Enrollment

Unknown

Registered

2022-07-06

Start date

2022-07-05

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Disease

Interventions

1:administration of remimazolam

Eligibility

Sex/Gender

All

Age

3 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1. Pediatric patients to undergo elective general anesthesia surgery, ASA physical status I or II; 2. Aged 3-7 years; 3. BMI 15-20 kg/m2; 4. The legal guardian of the children volunteered to participate in this experiment and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Acute upper respiratory tract infection/recovery period; 2. Allergic to remimazolam; 3. Severe systemic diseases.

Design outcomes

Primary

Measure	Time frame
MOAA/S score, modified obsevers assessment of alertness/sedation scale;bispectral index;	—

Secondary

Measure	Time frame
the time to MOAA/S <= 1;the time to bispectral index <= 60;Blood pressure;Heart rate;SpO2;Duration of awakening;Duration of PACU;Adverse effect;	—

Countries

China

Contacts

Public ContactWeixiang Tang

The First Affiliated Hospital of Anhui Medical University

vanillatang@163.com+86 13855161820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026